30AA Limited Human
CJC-1295 DAC
Long-acting albumin-binding GHRH analogue that sustains GH and IGF-1 elevation for up to 8 days from a single weekly injection.
In Plain English: CJC-1295 DAC is a 30-amino-acid synthetic copy of GHRH engineered with two upgrades: amino acid substitutions block enzymatic degradation, and a maleimidopropionyl 'hook' (DAC) latches onto circulating albumin for week-long persistence. A single shot raises GH 2-10x for ~6 days and IGF-1 up to 3x for 9-11 days, while preserving natural pulsatile GH rhythm.
Research Maturity
Limited Human (29 CJC-1295 papers indexed on PubMed; 2 human RCTs+ Studies)
Quick Facts
Focus
Body Composition
Hormone Modulation
Metabolic Health
Route
SubQ
Origin
Developed by ConjuChem Biotechnologies (Montreal) early 2000s. Core scaffold is modified Sermorelin (GHRH 1-29) with D-Ala2, Ala15, Leu27 substitutions for DPP-IV resistance. Lys30 carries maleimidopropionyl DAC linker for covalent albumin conjugation. Phase II trials halted after unrelated subject death.
Mechanism
GHRHR agonist at pituitary somatotrophs. Albumin conjugation extends t1/2 to 5.8-8.1 days. Triggers Gs-cAMP-PKA cascade for pulsatile GH secretion. Basal trough GH rises ~7.5x; mean GH +46%; IGF-1 +45%. Natural GH pulse frequency preserved. No elevation of prolactin, FSH, LH, TSH, or cortisol.
Outcome
Mean plasma GH 2-10x baseline for >=6 days; serum IGF-1 1.5-3x for 9-11 days; sustained IGF-1 >28 days with repeat dosing; GH pulsatility preserved.
Safety Flags & Warnings
Sustained GH Bleed (Cannot Abort Quickly)
WADA Prohibited
Injection Site Reactions (15-25%)
Insulin Resistance Risk
Potential Immunogenicity
Always consult a licensed physician. Research purposes only.
€11.5 / mg
